Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2000
09/05/2000CA2047686C Dietary supplement for insulin-resistant diabetics
09/05/2000CA2047685C Purified insulin mediators and purification process for same
09/05/2000CA2045593C Use of 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
09/05/2000CA2001160C Pyridine derivatives
09/05/2000CA1341093C Method and composition for preventing surgical adhesions
08/2000
08/31/2000WO2000050872A2 A system for cell-based screening
08/31/2000WO2000050618A1 Virus vector
08/31/2000WO2000050605A1 Avermectin aglycon synthase genes
08/31/2000WO2000050590A1 Mdm interacting protein and methods of use thereof
08/31/2000WO2000050562A2 Dna encoding snorf25 receptor
08/31/2000WO2000050454A1 Androgen-induced suppressor of cell proliferation and uses thereof
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050434A1 Malto-oligosaccharide derivatives and uses thereof
08/31/2000WO2000050431A1 Platinum (ii) compounds
08/31/2000WO2000050428A1 Process for preparing (-)pyridobenzoxazine carboxylic acid derivatives
08/31/2000WO2000050427A1 Optically pure camptothecin analogues
08/31/2000WO2000050425A1 Polycyclo heterocyclic derivatives as antiinflammatory agents
08/31/2000WO2000050423A1 C-21 modified epothilones
08/31/2000WO2000050420A1 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000WO2000050416A1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000WO2000050414A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them
08/31/2000WO2000050408A1 Pyridazin-3-one derivatives and medicines containing the same
08/31/2000WO2000050403A1 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
08/31/2000WO2000050401A1 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
08/31/2000WO2000050400A1 2-aminopyridines containing fused ring substituents
08/31/2000WO2000050399A1 Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
08/31/2000WO2000050398A2 Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
08/31/2000WO2000050396A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
08/31/2000WO2000050395A1 Sulfonamide-containing indole compounds
08/31/2000WO2000050392A1 2-mercaptocarboxylic acid derivatives
08/31/2000WO2000050391A1 Novel sulfonamide compounds and uses thereof
08/31/2000WO2000050380A1 Monoamine reuptake inhibitors for treatment of cns disorders
08/31/2000WO2000050090A2 Dry acid-chitosan complexes
08/31/2000WO2000050084A1 Stable formulation containing fumagillin
08/31/2000WO2000050083A1 Enteral sorbefacients
08/31/2000WO2000050082A1 Combination therapy for lymphoproliferative diseases
08/31/2000WO2000050067A1 Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
08/31/2000WO2000050066A1 Treatment of infertility
08/31/2000WO2000050065A1 Treatment of infertility
08/31/2000WO2000050062A2 Methods and compositions for altering mucus secretion
08/31/2000WO2000050047A2 Composition for the treatment of psoriasis
08/31/2000WO2000050043A1 Methods of treatment of mitochondrial disorders
08/31/2000WO2000050042A1 Methods for the treatment of apolipoprotein e related diseases
08/31/2000WO2000050040A1 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
08/31/2000WO2000050039A1 Agent for use in transplantation
08/31/2000WO2000050038A1 Pharmaceutical composition containing proton pump inhibitors
08/31/2000WO2000050037A1 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
08/31/2000WO2000050036A1 Storage stable amoxycillin and clavulanate suspension composition
08/31/2000WO2000050035A2 Premixed formulation of piperacillin sodium and tazobactam sodium injection
08/31/2000WO2000050034A1 Gaba receptors mediate inhibition of t cell responses
08/31/2000WO2000050032A1 Antitumour synergistic composition
08/31/2000WO2000050031A1 Co-administration of lucanthone and radiation for treatment of cancer
08/31/2000WO2000050030A1 New use
08/31/2000WO2000050029A1 Seam soft capsule preparations containing dihydrobenzofuran derivative
08/31/2000WO2000050028A1 Compositions for the treatment of pain
08/31/2000WO2000050027A1 Gabapentin derivative for preventing and treating visceral pain
08/31/2000WO2000050026A1 Gardos channel antagonists
08/31/2000WO2000050025A1 Topic tricyclic antidepressants as analgesics
08/31/2000WO2000050024A2 Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
08/31/2000WO2000050023A2 Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases
08/31/2000WO2000050022A2 Treatment regimen for hormone-sensitive cancers
08/31/2000WO2000050021A2 Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
08/31/2000WO2000050020A2 Use of sulfamate derivatives for treating impulse control disorders
08/31/2000WO2000050019A2 USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-λB
08/31/2000WO2000050018A2 Pharmaceutical preparation containing dithranol
08/31/2000WO2000050017A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
08/31/2000WO2000050015A1 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
08/31/2000WO2000050011A1 Controlled release formulation for treating copd
08/31/2000WO2000050009A1 Methods for administering pharmacologically active compounds to vertebrates
08/31/2000WO2000050007A1 Compositions and methods for improved delivery of hydrophobic therapeutic agents
08/31/2000WO2000050005A1 Liquid suppository composition of diclofenac sodium
08/31/2000WO2000050002A1 Reduction of hair growth
08/31/2000WO2000049994A1 An aqueous non-alcoholic oral rinse containing benzocaine and carbomer
08/31/2000WO2000049993A2 Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
08/31/2000WO2000049992A2 USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
08/31/2000WO2000049937A2 Trpm-2 antisense therapy
08/31/2000WO2000049896A1 Dietary compositions and methods
08/31/2000WO2000036113A3 Extending graft survival by heme oxygenase-i expression induced immunomodulation
08/31/2000WO2000033667A3 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants
08/31/2000WO2000030623A3 Agent for lowering prolactin
08/31/2000WO2000030611A3 Pharmaceutical preparation
08/31/2000WO2000027849A3 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
08/31/2000WO2000027382A3 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
08/31/2000WO2000027196A8 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
08/31/2000WO2000026236A3 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function
08/31/2000WO2000025805A8 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2
08/31/2000WO2000025753A3 Controlled delivery of active agents
08/31/2000WO2000023112A9 Modulation of gene expression by combination therapy
08/31/2000WO2000023055A9 Oral pulsed dose drug delivery system
08/31/2000WO2000021548A3 Angiogenically effective unit dose of fgf and method of administering
08/31/2000WO2000020601A9 Polyketide synthase enzymes and recombinant dna constructs therefor
08/31/2000WO2000019823A9 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
08/31/2000WO2000019200A9 Identifying agents that alter mitochondrial permeability transition pores
08/31/2000WO2000018910A9 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
08/31/2000WO2000015768A9 Immune activation by double-stranded polynucleotides
08/31/2000WO2000012507A3 Pyrrolobenzodiazepines
08/31/2000WO2000012074A3 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
08/31/2000WO2000007996A3 Pyrazoles as estrogen receptor modulators
08/31/2000WO2000001375A3 Calcium channel blockers
08/31/2000WO1999042086A9 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent
1 ... 6253 6254 6255 6256 6257 6258 6259 6260 6261 6262 6263 6264 6265 6266 6267 6268 6269 6270 6271 6272 6273 ... 7860